Kodiak Sciences Inc (KOD) News

Kodiak Sciences Inc (KOD): $7.74

0.14 (+1.84%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KOD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 384

in industry

Filter KOD News Items

KOD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KOD News Highlights

  • KOD's 30 day story count now stands at 3.
  • Over the past 15 days, the trend for KOD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest KOD News From Around the Web

Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.

Owning 44% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD),

If you want to know who really controls Kodiak Sciences Inc. ( NASDAQ:KOD ), then you'll have to look at the makeup of...

Yahoo | September 22, 2022

Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2022

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time (4:05 p.m. Eastern Time).

Yahoo | September 7, 2022

Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why

Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.

Yahoo | August 26, 2022

Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab

Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.

Yahoo | August 19, 2022

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology

Yahoo | August 18, 2022

Morgan Stanley Sticks to Their Hold Rating for Kodiak Sciences (KOD)

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Kodiak Sciences (KOD - Research Report) today and set a price target of $12.00. The company's shares opened today at $12.05.Harrison covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Regeneron, and Alnylam Pharma. According to TipRanks, Harrison has an average return of 7.6% and a 52.94% success rate on recommended stocks. In addition to Morgan Stanley, Kodiak Sciences also received a Hold from Goldman Sachs's Andrea Tan in a report issued on August 9. However, on August 10, Chardan Capital maintained a Buy rating on Kodiak Sciences (NASDAQ: KOD).

Catie Powers on TipRanks | August 15, 2022

Chardan Capital Sticks to Their Buy Rating for Kodiak Sciences (KOD)

Chardan Capital analyst Daniil Gataulin maintained a Buy rating on Kodiak Sciences (KOD - Research Report) today and set a price target of $18.00. The company's shares opened today at $10.91.Gataulin covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Applied Genetic Technologies, and Kodiak Sciences. According to TipRanks, Gataulin has an average return of -0.1% and a 60.00% success rate on recommended stocks. Kodiak Sciences has an analyst consensus of Hold, with a price target consensus of $11.43, a 4.77% upside from current levels. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $15.00 price target.

Catie Powers on TipRanks | August 10, 2022

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus

Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.

Yahoo | August 10, 2022

Goldman Sachs Sticks to Their Hold Rating for Kodiak Sciences (KOD)

E ratio of (1.85).

Ryan Adist on TipRanks | August 9, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4947 seconds.